Patents by Inventor David M. Knight

David M. Knight has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12065488
    Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.
    Type: Grant
    Filed: November 1, 2021
    Date of Patent: August 20, 2024
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution, Inc.
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Publication number: 20220048985
    Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.
    Type: Application
    Filed: November 1, 2021
    Publication date: February 17, 2022
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Patent number: 11180549
    Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: November 23, 2021
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution, Inc
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Patent number: 11078267
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: August 3, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20200115445
    Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.
    Type: Application
    Filed: December 17, 2019
    Publication date: April 16, 2020
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Publication number: 20200062841
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.
    Type: Application
    Filed: November 7, 2019
    Publication date: February 27, 2020
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Patent number: 10519231
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: December 31, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20190248884
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.
    Type: Application
    Filed: February 25, 2019
    Publication date: August 15, 2019
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Patent number: 10259867
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: April 16, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20180334500
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
    Type: Application
    Filed: May 1, 2017
    Publication date: November 22, 2018
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Patent number: 9828424
    Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: November 28, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
  • Publication number: 20170253651
    Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.
    Type: Application
    Filed: March 17, 2017
    Publication date: September 7, 2017
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xioa-yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Patent number: 9676848
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: June 13, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Patent number: 9631016
    Abstract: A pen-injector device comprising an anti-IL-6 antibody with a liquid formulation have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: April 25, 2017
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Publication number: 20170029496
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
    Type: Application
    Filed: June 30, 2016
    Publication date: February 2, 2017
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20160264659
    Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and thera
    Type: Application
    Filed: March 21, 2016
    Publication date: September 15, 2016
    Applicant: Janssen Biotech, Inc.
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
  • Patent number: 9409984
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: August 9, 2016
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20160222104
    Abstract: A pen-injector device comprising an anti-IL-6 antibody with a liquid formulation have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: April 19, 2016
    Publication date: August 4, 2016
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Patent number: 9340613
    Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: May 17, 2016
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Patent number: 9321836
    Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS: 1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: April 26, 2016
    Assignee: Janssen Biotech, Inc.
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy